Loading...
XNASMEDS
Market cap13mUSD
Sep 20, Last price  
7.59USD
Name

TRxADE Health Inc

Chart & Performance

D1W1MN
XNAS:MEDS chart
P/E
P/S
1.61
EPS
Div Yield, %
0.00%
Shrs. gr., 5y
43.72%
Rev. gr., 5y
16.64%
Revenues
8m
-27.74%
000806,047955,8811,496,2274,992,2032,481,8662,931,2803,831,7787,436,26417,122,5209,889,43311,448,2658,272,214
Net income
-18m
L+313.98%
-8,725-28,186-28,497,000-150,713-2,091,285-2,012,043-1,117,183-2,760,125288,9839,038-409,730-2,565,440-4,113,047-4,310,205-17,843,574
CFO
-2m
L+35.89%
-6,225-16,068-28,164,000-163,118-844,579-1,064,576-1,202,137-1,313,418171,670273,386141,775-2,214,786-2,566,226-1,525,929-2,073,601
Dividend
Jul 19, 20241.5 USD/sh
Earnings
Jan 14, 2025

Profile

TRxADE HEALTH, Inc. operates as a health services IT company in the United States. The company focuses on digitalizing the retail pharmacy experience by optimizing drug procurement, prescription journey, and patient engagement. It operates the TRxADE drug procurement marketplace, which fosters price transparency and serves approximately 11,800 members; and offers patient centric telehealth services under the Bonum Health brand name. The company was formerly known as Trxade Group, Inc. and changed its name to TRxADE HEALTH, Inc. in June 2021. TRxADE HEALTH, Inc. is based in Land O' Lakes, Florida.
IPO date
Feb 18, 2020
Employees
33
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
8,272
-27.74%
11,448
15.76%
9,889
-42.24%
Cost of revenue
15,536
14,205
15,323
Unusual Expense (Income)
NOPBT
(7,263)
(2,757)
(5,434)
NOPBT Margin
Operating Taxes
5,336
400
(1,203)
Tax Rate
NOPAT
(12,599)
(3,157)
(4,231)
Net income
(17,844)
313.98%
(4,310)
4.79%
(4,113)
60.33%
Dividends
Dividend yield
Proceeds from repurchase of equity
518
131
17
BB yield
-4.19%
-57.56%
-1.31%
Debt
Debt current
6,809
364
179
Long-term debt
1,392
2,304
2,318
Deferred revenue
Other long-term liabilities
(409)
Net debt
8,050
1,534
(626)
Cash flow
Cash from operating activities
(2,074)
(1,526)
(2,566)
CAPEX
(451)
(23)
Cash from investing activities
(276)
(428)
(23)
Cash from financing activities
1,406
(35)
(208)
FCF
(9,474)
(2,438)
(2,702)
Balance
Cash
152
1,134
3,123
Long term investments
Excess cash
561
2,628
Stockholders' equity
(33,246)
(20,140)
(16,247)
Invested Capital
40,211
22,066
21,266
ROIC
ROCE
EV
Common stock shares outstanding
2,381
565
542
Price
5.20
1,190.69%
0.40
-82.94%
2.36
-55.47%
Market cap
12,375
5,341.49%
227
-82.24%
1,280
-52.98%
EV
20,425
1,341
655
EBITDA
(6,214)
(2,561)
(5,295)
EV/EBITDA
Interest
1,198
336
24
Interest/NOPBT